Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q2 2022 Earnings Conference Call August 3, 2022 8:00 AM ET
Company Participants
Bennett Watson - ICR Westwicke, Investor Relations
Dan Barber - Chief Executive Officer
Ernie Toth - Chief Financial Officer
Dr. Steve Wargacki - VP of R&D
Ken Marshall - Chief Commercial Officer.
Conference Call Participants
Evan Hua - BMO Securities
Jason Butler - JMP Securities
Thomas Flaten - Lake Street Capital
Andreas Argyrides - Wedbush
Ram Selvaraju - H.C. Wainwright
James Molloy - Alliance Global
Operator
Good morning, and welcome to the Aquestive Therapeutics Second Quarter 2022 Conference Call. [Operator Instructions] As a reminder, this call will be recorded.
I would now like to introduce your host for today’s conference call, Bennett Watson of ICR Westwicke, Investor Relations. You may begin.
Bennett Watson
Thank you, operator. Good morning, and welcome to today's call. On today's call, I am joined by Dan Barber, Chief Executive Officer; and Ernie Toth, Chief Financial Officer, who are going to provide an overview of recent business developments and performance for second quarter 2022, followed by a Q&A session. During the Q&A session, the team will be joined by Dr. Steve Wargacki, VP of R&D; and Ken Marshall, Chief Commercial Officer.
As a reminder, the company's remarks today correspond with their earnings release that was issued after market close yesterday. In addition, a recording of today's call will be made available on Aquestive's website within the Investors section shortly following the conclusion of this call. To remind you, the Aquestive team will be discussing some non-GAAP financial measures this morning as part of its review of second quarter 2022 results. A description of these measures, along with a reconciliation to GAAP, can be found in the earnings release issued yesterday, which is posted on the Investors section of Aquestive's website.
During the call, the company will be making forward-looking statements. We remind you of the company's safe harbor language as outlined in yesterday's earnings release as well as the risks and uncertainties affecting the company as described in the Risk Factors section and other sections included in our annual report on Form 10-K filed with the Securities and Exchange Commission on March 8, 2022, and in our quarterly reports on Form 10-Q and current reports on Form 8-K filed with the SEC.
As with any pharmaceutical company with product candidates under development and products being commercialized, there are significant risks and uncertainties with respect to the company's business and the development, regulatory approval and commercialization of its products and other matters related to operations. The impact of the ongoing COVID-19 pandemic is highly uncertain and cannot be predicted with certainty or clarity. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. Actual results may differ materially from these statements. All forward-looking statements attributable to Aquestive or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement and the cautionary statements contained in the earnings release issued yesterday. The company assumes no obligation to update its forward-looking statements after the date of this conference call, whether as a result of new information, future events or otherwise, except as required under applicable law.